Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment

The HRD (Homologous Recombination Deficiency) test is considered a genomic alteration useful for guiding therapeutic decisions in patients with ovarian cancer. Some commercial and in house alternative “academic” tests are available. Recent findings indicate that not all <i>BRCA1/2</i> mu...

Full description

Saved in:
Bibliographic Details
Main Authors: Giovanni Luca Scaglione, Valentina Lombardo, Maurizio Polano, Giuseppa Scandurra, Angela Pettinato, Corrado Giunta, Rosario Iemmolo, Paolo Scollo, Ettore D. Capoluongo
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Biomolecules
Subjects:
Online Access:https://www.mdpi.com/2218-273X/15/5/745
Tags: Add Tag
No Tags, Be the first to tag this record!